Healthcare tech company Omnicell (NASDAQ: OMCL) will be announcing earnings results this Thursday morning. Here’s what investors should know.

Omnicell beat analysts’ revenue expectations last quarter, reporting revenues of $309.9 million, up 14.9% year on year. It was an exceptional quarter for the company, with EBITDA guidance for next quarter exceeding analysts’ expectations and a beat of analysts’ EPS estimates.

Is Omnicell a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Omnicell’s revenue to grow 6.8% year on year, improving from the 5% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Omnicell rarely misses Wall Street’s revenue estimates.

With Omnicell being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for healthcare technology stocks. However, there has been positive investor sentiment in the segment, with share prices up 4.4% on average over the last month. Omnicell is up 3.6% during the same time .

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.